These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993 [TBL] [Abstract][Full Text] [Related]
3. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2. Pack LR; Daigh LH; Chung M; Meyer T Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27. Coulonval K; Vercruysse V; Paternot S; Pita JM; Corman R; Raspé E; Roger PP Cell Cycle; 2022 Jan; 21(1):12-32. PubMed ID: 34913830 [TBL] [Abstract][Full Text] [Related]
5. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033 [TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. Paternot S; Coulonval K; Dumont JE; Roger PP J Biol Chem; 2003 Jul; 278(29):26533-40. PubMed ID: 12730225 [TBL] [Abstract][Full Text] [Related]
7. Distinct specificities of pRb phosphorylation by CDK4 activated by cyclin D1 or cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells. Paternot S; Arsenijevic T; Coulonval K; Bockstaele L; Dumont JE; Roger PP Cell Cycle; 2006 Jan; 5(1):61-70. PubMed ID: 16294008 [TBL] [Abstract][Full Text] [Related]
8. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence. Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870 [TBL] [Abstract][Full Text] [Related]
9. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cabrera MC; Díaz-Cruz ES; Kallakury BV; Pishvaian MJ; Grubbs CJ; Muccio DD; Furth PA Cancer Prev Res (Phila); 2012 Jun; 5(6):810-21. PubMed ID: 22508966 [TBL] [Abstract][Full Text] [Related]
10. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. Colleoni B; Paternot S; Pita JM; Bisteau X; Coulonval K; Davis RJ; Raspé E; Roger PP Oncogene; 2017 Jul; 36(30):4349-4361. PubMed ID: 28368408 [TBL] [Abstract][Full Text] [Related]
11. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Bockstaele L; Bisteau X; Paternot S; Roger PP Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459 [TBL] [Abstract][Full Text] [Related]
13. Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations by growth factors and TSH of human thyrocytes in primary culture. Paternot S; Dumont JE; Roger PP Mol Endocrinol; 2006 Dec; 20(12):3279-92. PubMed ID: 16916940 [TBL] [Abstract][Full Text] [Related]
15. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells. Said TK; Medina D Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257 [TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells. Wang D; Sun Y; Li W; Ye F; Zhang Y; Guo Y; Zhang DY; Suo J Int J Mol Med; 2018 May; 41(5):2473-2484. PubMed ID: 29436583 [TBL] [Abstract][Full Text] [Related]